Waters (WAT) Resumen de Acciones
Waters Corporation ofrece soluciones de flujo de trabajo analítico en Asia, América y Europa. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
WAT Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.4% infravalorado descuento intrínseco
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCompetidores de Waters Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$350.49 |
| Máximo en las últimas 52 semanas | US$414.15 |
| Mínimo de 52 semanas | US$275.05 |
| Beta | 1.14 |
| Cambio en 1 mes | 14.03% |
| Variación en 3 meses | -8.08% |
| Cambio de 1 año | -0.11% |
| Variación en 3 años | 30.31% |
| Variación en 5 años | 11.10% |
| Variación desde la OPV | 9,169.16% |
Noticias y actualizaciones recientes
Actualización del análisis • May 01
WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside
Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).
Actualización del análisis • Apr 17
WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check
Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.Recent updates
Actualización del análisis • May 01
WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside
Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).Actualización del análisis • Apr 17
WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check
Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.
Actualización del análisis • Apr 03
WAT: New Four Division Model And Materials Focus Will Support Higher Profitability
Analysts have reduced their price target on Waters by about $5 to $393, reflecting small adjustments to fair value assumptions, discount rate, revenue growth, profit margin and future P/E inputs. What's in the News Waters launched the TA Instruments ARES-G3 Rheometer, a next generation system that captures up to 25,000 data points per second, aims to shorten standard test times by up to 80%, and is available for order as part of the materials characterization portfolio (Key Developments).Actualización del análisis • Mar 20
WAT: New Four Division Model Will Support Higher Long Term Profitability
Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.Seeking Alpha • Mar 10
Waters: Doing Well, Acquired Activities Not So Much
Summary Waters' shares have retreated to the $300 level, presenting a renewed buying opportunity after initial post-acquisition gains evaporated. The $17.5B acquisition of Becton, Dickinson's Biosciences & Diagnostics Solutions expands Waters scale, though acquired business growth appears soft versus initial expectations. Waters guides 2026 sales to $6.405–$6.455B and adjusted EPS to $14.30–$14.50, reflecting early synergies and manageable leverage. At 21x earnings, Waters is not historically cheap, but synergy potential and deleveraging support a more upbeat outlook at current levels. Read the full article on Seeking AlphaActualización del análisis • Mar 05
WAT: New Four Division Structure Will Support Higher Long Term Earnings
Analysts have nudged their price target for Waters higher to $398.05 from $394.68, reflecting updated assumptions that combine a higher revenue growth outlook, a lower projected profit margin, and a richer future P/E multiple. What's in the News Waters has closed a transaction and reorganized into four divisions, aligning its operations with high volume testing in regulated applications and adjacent markets such as therapeutics, food, environmental testing, and specialty diagnostics (Key Developments).Actualización del análisis • Feb 19
WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now
Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).Actualización del análisis • Feb 05
WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists
Analysts have modestly lifted their price target for Waters to about $349, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of this small adjustment from roughly $348.15. What's in the News Waters has scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat in the United States (Key Developments).Actualización del análisis • Jan 22
WAT: New Detector Launch And Stable Margins Will Support Future Upside
Analysts kept their price target for Waters steady at US$480.00, with only very small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, reflecting fine-tuning rather than a major shift in their view. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held via proxydocs.com/wat in the United States (company event filing).Actualización del análisis • Jan 08
WAT: Higher Margins And New Product Launch Will Support Future Upside
Analysts have lifted their price target on Waters to US$480 from about US$424, citing updated assumptions for slightly higher revenue growth, profit margins near 26%, and a modestly higher future P/E multiple. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat (Special/Extraordinary Shareholders Meeting).Artículo de análisis • Jan 04
Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)
Key Insights Waters' estimated fair value is US$362 based on 2 Stage Free Cash Flow to Equity Waters' US$382 share...Actualización del análisis • Dec 25
WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism
Analysts have raised their price target on Waters from 300.00 dollars to 348.15 dollars, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Launched a new Charged Aerosol Detector optimized for Empower Software, expanding capabilities for measuring analytes with little or no UV absorption across pharmaceuticals, food, and environmental testing, with shipments expected by April 2026 (company product announcement).Actualización del análisis • Dec 10
WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook
Narrative Update on Waters Analysts have modestly raised their price target on Waters by approximately $6 per share, reflecting slightly lower discount rate assumptions, a small improvement in projected profit margins, and a marginally higher future P/E multiple that together support a higher fair value estimate. What's in the News Launched a new Charged Aerosol Detector, purpose built for Empower chromatography software, expanding Waters portfolio of LC detectors and strengthening its position in compliant, high sensitivity analysis for low UV analytes, with shipments expected by April 2026 (Key Developments) Unveiled the Xevo Charge Detection Mass Spectrometer to enable high resolution characterization of very large biomolecules that are central to next generation therapeutics, leveraging technology acquired from Indiana University and Megadalton Solutions (Key Developments) Raised full year 2025 guidance and now expects constant currency sales growth of 6.7% to 7.3% and GAAP EPS of 11.10 to 11.20 dollars per diluted share (Key Developments) Issued new guidance for the fourth quarter of 2025, targeting constant currency sales growth of 5.0% to 7.0% and GAAP EPS of 4.10 to 4.20 dollars per diluted share (Key Developments) Completed its multi year share repurchase program announced in January 2019, buying back more than 15.1 million shares for approximately 3.8 billion dollars in total consideration (Key Developments) Valuation Changes The fair value estimate has risen slightly to approximately $395 per share from about $389 per share, reflecting modest valuation upside.Actualización del análisis • Nov 26
WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends
Narrative Update on Waters: Analyst Price Target Revision Analysts have raised their price target for Waters, increasing the fair value estimate by $5.71 to $388.58. This revision is attributed to improved profit margin projections, even as revenue growth expectations have slowed.Actualización del análisis • Nov 07
WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead
Analysts have raised their price target for Waters from $355.74 to $382.87. They cite significantly higher expected revenue growth, which outweighs a slight decrease in projected profit margins.Actualización del análisis • Oct 23
Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities
Narrative Update on Waters Analysts have slightly raised their price target for Waters from $351.07 to $355.74. This change is attributed to modest improvements in projected revenue growth and fair value estimates.Actualización del análisis • Oct 09
Pharmaceutical R&D And Merger Will Unlock Future Market Potential
Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.Artículo de análisis • Sep 19
Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)
Waters Corporation's ( NYSE:WAT ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right now...Actualización del análisis • Sep 04
Pharmaceutical R&D And Merger Will Unlock Future Market Potential
With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.Artículo de análisis • Jul 24
Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Waters fair value estimate is US$465 Waters is estimated to be...Artículo de análisis • Jul 06
These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Feb 21
Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern
Summary Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers. I rate Waters Corp as a 'hold' due to solid recovery and growth potential, but caution investors to consider the premium pricing relative to value. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
Weighing In On Waters Corporation: Facing A Valuation Headwind
Summary Today, we take a more in-depth look at Waters Corporation, which provides analytical workflow solutions, primarily to the Pharma and Industrial industries. WAT stock has surged 35% since July lows, but analysts are growing increasingly cautious due to valuation concerns, with mixed ratings and tepid price targets. From a historical perspective, the equity now trades at the very top of its historical P/S and P/E ratios. Can WAT shares rally with this valuation headwind? An analysis of Waters Corporation follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Waters Corp: Short Reinvestment Runway Diminishes High Multiples
Summary Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still a drag on performance. Opportunities to redeploy surplus funds at an advantage appear limited, reducing compounding ability. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Waters Corp.: Embedded Expectations High Under Present Conditions
Summary Waters continues to present with high-quality business characteristics, including high returns on capital employed and loads of freely available cash. Embedded expectations remain exquisitely high, calling for outsized performance in a time when business returns may be contracting. Present multiples demand high compounding rate of operating capital, which reduces the margin of safety. Reiterate hold. Read the full article on Seeking AlphaSeeking Alpha • May 24
Waters Corporation: Still Struggling A Bit
Summary Waters Corporation reported mediocre first quarter results with the top and bottom line declining. According to fiscal 2024 guidance, the company is still not expecting growth but due to the wide economic moat, we should be optimistic for long-term growth. At this point, Waters Corporation is fairly valued at best and still not a great investment. Read the full article on Seeking AlphaSeeking Alpha • Mar 11
Waters Corporation: A Great (Share Price) Run
Summary Waters Corporation stock has seen strong momentum, rising over $100 per share in a short period of time. The company serves regulated markets with high-quality solutions and has a recurring revenue business model. After a tough 2023 and non-convincing outlook for 2024, I am surprised by the share price momentum, making me pleased to take profits in Waters Corporation stock here. Read the full article on Seeking AlphaSeeking Alpha • Dec 28
Waters Corporation: High Quality Niche Company In Mass Spectrometry
Summary Waters is a niche player in the liquid chromatography, mass spectrometry, and thermal analysis markets, with a simple and profitable business model. The company's focus on product innovation and acquisitions contributes to its growth and competitive advantage. However, Waters faces headwinds in the Chinese market, which may impact its growth in the near term. Read the full article on Seeking AlphaRentabilidad de los accionistas
| WAT | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 13.3% | 1.8% | 2.1% |
| 1Y | -0.1% | 7.7% | 30.6% |
Rentabilidad vs. Industria: Los resultados de WAT fueron inferiores a los de la industria US Life Sciences, que obtuvo un rendimiento del 7.7% el año pasado.
Rentabilidad vs. Mercado: WAT obtuvo unos resultados inferiores a los del mercado US, que fueron del 30.6% el año pasado.
Volatilidad de los precios
| WAT volatility | |
|---|---|
| WAT Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: WAT no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de WAT (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1958 | 16,000 | Udit Batra | www.waters.com |
Waters Corporation ofrece soluciones de flujo de trabajo analítico en Asia, América y Europa. La empresa opera a través de dos segmentos, Waters y TA. La empresa diseña, fabrica, vende y presta servicios de cromatografía líquida, así como sistemas de tecnología de espectrometría de masas (EM) y productos de apoyo, incluidas columnas de cromatografía y otros productos consumibles.
Resumen de fundamentos de Waters Corporation
| Estadísticas fundamentales de WAT | |
|---|---|
| Capitalización bursátil | US$34.31b |
| Beneficios(TTM) | US$449.63m |
| Ingresos (TTM) | US$3.77b |
76.5x
Ratio precio-beneficio (PE)9.1x
Ratio precio-ventas (PS)¿Está WAT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de WAT | |
|---|---|
| Ingresos | US$3.77b |
| Coste de los ingresos | US$1.58b |
| Beneficio bruto | US$2.19b |
| Otros gastos | US$1.74b |
| Beneficios | US$449.63m |
Últimos beneficios comunicados
Apr 04, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 4.58 |
| Margen bruto | 57.97% |
| Margen de beneficio neto | 11.93% |
| Ratio deuda/patrimonio | 34.1% |
¿Cómo se ha desempeñado WAT a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 21:46 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2026/04/04 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Waters Corporation está cubierta por 39 analistas. 21 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |